A venture capital firm dedicated to bringing bioelectronic medicines to patients.

Action Potential Venture Capital

Action Potential Venture Capital (APVC) is GSK's bioelectronic medicines venture fund.  APVC is focused on the next generation of peripheral neuromodulation medical devices, and invests in companies and technologies that enable the future of targeted and adaptive bioelectronics.

CVRx

Congratulations to the team, investors, founders and clinical trial participants involved with this landmark pivotal study!

More to come, but an exciting day for this novel therapy under investigation for Rheumatoid Arthritis and other autoimmune diseases. 

#intelligentmedicine #bioelectronicmedicine

Big announcements from Cala Health today ⚡️ 🧠
1) 75% of ET patient's now have access to Cala kIQ therapy via CMS's positive coverage determination, and 

2) We are thrilled to name Deanna Harshbarger CEO to lead the company during this exciting next phase of growth and accessibility for essential tremor and parkinson's disease patients! 

#bioelectronicmedicine #electricityasmedicine #essentialtremor #parkinsonsdisease #CMS #Medicare #CEO

Action Potential Venture Capital portfolio company, Exo’s workflow solution is revolutionizing healthcare, streamlining processes, and enhancing patient care.

Since implementing Exo Works™, Wellstar Health System Health System has:

- Seen a remarkable 47% increase in revenue capture. 

- Achieved a 203% rate of return after nine months and broke even in 3 months. 

- Raised its QA percentage from 10% to 100% for all POCUS exams—including those conducted by residents and medical students 

Read more about the power of Exo here: https://lnkd.in/gBbSYReC

#ExoWorks #Exo #POCUS #Ultrasound
#MedicalImaging #HealthTech #MedTech
#FOAMed #MedEd

👏🏽👏🏽 to SetPoint Medical for receiving Breakthrough Designation in #MultipleSclerosis from the FDA.  Given the limitations of traditional molecular medicines in #MS, Action Potential has tremendous hope for the power of SetPoint's vagus nerve microregulator, to potentially remyelinate nerves in patients suffering with MS.  We join the many who are looking forward to clinical evaluation of this #bioelectronic therapeutic approach for a relapsing-remitting patient group.

#msawareness #inflammatoryreflex #neurotech

Suraj Mudichintala shared his perspectives on the broader Neurotech markets along side a distinguished panel with Sara Shnider, Martin Dieck, and JoJo Platt. The future of Neurotech is bright!

Thrilled to see Exo and Cala Health, both Action Potential Venture Capital portfolio companies, recognized on the Medtech Fierce 15!

https://lnkd.in/eUDaU-Nm

#futureofmedicine #bioelectronics #closedloop #imaging #ai

ACTI

COM:ACTIONPOTENTIALVC

Action Potential Venture Capital